Figure 6From: Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model In vivo tumor growth assays. A. After tumor implantation into immunocompromised nude mice, animals were treated with lapatinib for four weeks at the indicated concentration. Tumor volumes in treated mice were smaller than those found in controls; B. Lapatinib significantly reduced tumor metabolism (P = 0.037), which was shown by the standardized glucose uptake values (SUV) measured with micro-PET.Back to article page